What is the price target for ATHE stock?
5 analysts have analysed ATHE and the average price target is 6.64 USD. This implies a price increase of 43.65% is expected in the next year compared to the current price of 4.62.
ALTERITY THERAPEUTICS-ADR (ATHE) Forecast, Price Target & Analyst Ratings
NASDAQ:ATHE • US02155X2053
Current stock price
4.62 USD
+0.21 (+4.76%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALTERITY THERAPEUTICS-ADR (ATHE).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$6.64
Upside
+ 43.65%
From current price of $4.62 to mean target of $6.64, Based on 5 analyst forecasts
Low
$6.57
Median
$6.64
High
$6.83
Price Target Revisions
1 Month
96.81%
3 Months
N/A
Price Target Summary
5 Wall Street analysts provided a forecast for the next 12 months for ATHE. The average price target is 6.64 USD. This implies a price increase of 43.65% is expected in the next year compared to the current price of 4.62.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
ATHE was analyzed by 5 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about ATHE.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed ATHE. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-17 | Canaccord Genuity | Initiate | Speculative Buy |
| 2025-01-30 | Maxim Group | Maintains | Buy -> Buy |
| 2024-12-12 | Maxim Group | Initiate | Buy |
| 2024-03-07 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-06-05 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2022-08-03 | Ladenburg Thalmann | Initiate | Buy |
| 2022-06-23 | Goldman Sachs | Maintains | Neutral |
| 2021-08-20 | Benchmark | Initiate | Speculative Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 16.4K 556.00% | 268.4K 1,536.59% | 446.3K 66.28% | -100.00% | 8.092M | 34.638M 328.05% | 136.23M 293.30% | 395.04M 189.98% | 586.23M 48.40% | |||
| EBITDA YoY % growth | N/A | N/A | N/A | -21.412M | -29.997M -40.09% | -38.279M -27.61% | -24.911M 34.92% | 28.42M 214.08% | 173.68M 511.12% | 355.4M 104.63% | 376.48M 5.93% | |
| EBIT YoY % growth | -14.622M 8.35% | -19.339M -32.26% | -14.215M 26.49% | -21.513M -51.34% | -28.684M -33.33% | -35.956M -25.35% | -36.96M -2.79% | -12.393M 66.47% | 66.832M 639.29% | 572.91M 757.24% | 846.86M 47.82% | |
| Operating Margin | -89,157.32% | -7,205.10% | -3,185.14% | N/A | N/A | N/A | -456.75% | -35.78% | 49.06% | 145.03% | 144.46% | |
| EPS YoY % growth | N/A | N/A | N/A | -59.53 | -59.53 | -59.53 | -28.46 52.20% | 0.00 100.00% | N/A | N/A | N/A |
All data in AUD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in AUD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-319.68%
EPS Next 5 Year
14.87%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
155.05%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-55.28%
EBIT Next 5 Year
36.74%
ALTERITY THERAPEUTICS-ADR / ATHE Forecast FAQ
How many analysts cover ALTERITY THERAPEUTICS-ADR (ATHE) stock?
The number of analysts covering ALTERITY THERAPEUTICS-ADR (ATHE) is 5.